**Association of PFKM gene polymorphisms and susceptibility to cryptorchidism in a Chinese Han population**

Siyu Long1,2 · Ran Zhang3 · Qinni Yang1,2 · Yanyun Wang2 · Yaping Song2 · Bin Zhou2 · Lin Zhang1,2

Accepted: 26 June 2022 / Published online: 15 July 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

**Abstract**

**Background** Cryptorchidism is one of the most common congenital anomalies in newborn boys. There are various risk factors that have been verified to have relationship with cryptorchidism, including exogenous and genetic, but the pathogenesis of cryptorchidism remains unclear. PFKM gene is a critical gene encodes for a regulatory enzyme, which limits the rate in the pathway of glycolysis. We assumed that cryptorchidism risk may associated with PFKM gene single-nucleotide polymorphisms (SNPs). Thus we selected three tag SNPs in the PFKM gene and aimed to investigate the possible association between PFKM gene polymorphisms and cryptorchidism risk.

**Methods** The SNPs were genotyped using polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) analysis. 140 cases and 227 controls were enrolled in this study, including 105 unilateral cryptorchidism and 35 bilateral cases. The testis position was decided by the higher one in bilateral cases.

**Results** The frequency of allele G of SNP rs2228500 is increased in cryptorchidism patients compared to that in controls \((p < 0.05)\). Genotypic frequencies of rs2228500 are associated with the susceptibility of cryptorchidism in the codominant model \((p < 0.05)\). And compared with G/G genotype in the dominant model, notable decreased frequencies of A carriers (A/G–A/A genotypes) were observed in cryptorchidism patients \((p = 0.0069, \text{OR} = 1.80, 95\% \text{CI } 1.17–2.75)\).

**Conclusions** This research first revealed that PFKM gene polymorphisms were associated with cryptorchidism in a Chinese Han population. We have offered primary evidence that the G allele and the G/G genotype of rs2228500 SNP in the PFKM gene are more frequent in patients with cryptorchidism than healthy controls.

**Keywords** Cryptorchidism · PFKM · Single-nucleotide polymorphisms (SNP) · Polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP)

---

**Introduction**

Cryptorchidism is a common congenital malformation in newborn boys, affecting 3–5% of the full-term-born male infants and up to 30% of preterm or low birth-weight male neonates [1]. It is a clinical finding in which one or both testicles fail to descend into the ipsilateral scrotum, also known as undescended testis (UDT). Sufficient evidence suggested that cryptorchidism (especially bilateral UDT) is one of the prevalent causes of male infertility, and it is also a higher risk factor for germ cell tumors [2, 3]. At present, the surgical operation is the first treatment for most patients with cryptorchidism, and the orchiopexy should be performed before 18 months age as far as possible to preserve the fertility of children and reduce the risk of testicular cancer in the future [4, 5].

---

1 Department of Immunology, West China School of Basic Medical Science and Forensic Medicine, Sichuan University, No. 17 Ren Min Nan Lu Chengdu, Sichuan 610041, China
2 Laboratory of Molecular Translational Medicine, Center for Translational Medicine, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital of Sichuan University, Sichuan University, No. 20 Ren Min Nan Lu, Chengdu 610041, Sichuan, China
3 Department of Cardiology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China
Typically, completely descended testes (CDT) is formed through a distinct, sequential two-stage descent, each involving multiple mechanical and hormonal factors [6]. The complexity of the biological mechanisms driving testicular descent is probably a vital factor in the complexity of the etiology of the disease. However, pieces of evidence proved environment and genetic factors may both play critical roles in the development of cryptorchidism [7]. In recent years, there has been an increasing interplay critical roles in the development of cryptorchidism. However, pieces of evidence have proven that environment and genetic factors may both play critical roles in the complexity of the biological mechanisms driving testicular descent.

Involving multiple mechanical and hormonal factors, through a distinct, sequential two-stage descent, each piece of evidence has proven that environment and genetic factors may both play critical roles in the complexity of the biological mechanisms driving testicular descent. In recent years, there has been an increasing interplay critical roles in the development of cryptorchidism. However, pieces of evidence have proven that environment and genetic factors may both play critical roles in the complexity of the biological mechanisms driving testicular descent.

The PFKM gene is located within a 41 kb region at chromosome 12q13.11. PFKM is the encoding gene for phosphofructokinase-M, which plays an important role in energy metabolism and muscle cell homeostasis. Phosphofructokinase-M is one of the key speed-limiting enzymes for glycolysis, and it is involved in the energy metabolism pathway through glycolysis [8]. In human cells, phosphofructokinase (PFK) is a tetrameric enzyme that is subjected to allosteric regulation. PFK consists of three isozyme types, which are liver-type (PFKL), platelet-type (PFKP), and muscle-type (PFKM). Tissue isozymes randomly aggregate to form homotetramers or heterotetramers depending on the relative abundance of the subunits in a particular tissue. PFKM is abundant mainly in skeletal muscles as a homotetramer and is expressed as a heterotetramer in erythrocytes and various other tissues [9]. In recent years, PFKM has attracted extensive attention in tumor research and many studies have shown that it is highly correlated with tumor cell growth [10–12]. Earlier in vivo studies have shown that PFK showed high activity in the rat testis during maturation [13, 14]. Furthermore, PFK activity is decreased in the testis in the early cryptorchidism [13]. The remarkable thing is a significant muscle movement is required during testicular descent [15]. Hence, PFKM may participate in the normal growth and development of testis and testicular diseases.

We speculated that the PFKM gene may associate with cryptorchidism risk. To reveal whether PFKM is involved in the development of cryptorchidism, we conducted a case–control study to assess the role of 3 tag SNPs of PFKM (rs2228500, rs4075913, and rs11168417) in patients with cryptorchidism. To our knowledge, this is the first study to evaluate the correlation between PFKM gene polymorphisms and cryptorchidism risk.

### Materials and methods

#### Study subjects

The retrospective study was approved by the Ethics Committee of the West China Hospital and written informed consent was obtained from all participants. 140 patients with cryptorchidism and 227 unrelated healthy volunteers were enrolled in this study, and all the patients were recruited from the West China Hospital from February 2017 to March 2020. The boys were examined shortly after birth and again at 3 months of age to determine. The examination technique and the definition of cryptorchidism developed by Scorer [16] were applied. All examinations for these children were performed in a supine position under warm conditions. Testicle position was recorded after manipulation of the testis to the farthest distal position along the pathway of normal descent using firm and non-forced traction. Re-confirmation of the diagnosis before orchidopexy was conducted when the patient is around 1 year old. 105 cases manifested unilateral cryptorchidism and 35 cases were bilateral cryptorchidism in the case group. The testis position was decided by the higher one in bilateral cases. Among patients, the testis of 46 cases was in the superficial inguinal pouch while 34 cases in the pre-scrotal region, 31 cases in the external ring, 19 cases in the inguinal canal, and 10 cases in the internal ring. The subjects in the control group (mean age 4.8 ± 1.2 years, range 1 month—14 years) were admitted for resection of foreskin. For individuals in both groups, premature or low birth-weight infants and any personal or family history of cryptorchidism or serious disease were excluded to avoid multifactorial effects. All the subjects were Chinese Han population living in the Sichuan Province of southwest China.

### SNP selection and genotyping

Tag SNPs are representative SNPs in genome regions with high linkage disequilibrium. Three tag SNPs of the PFKM gene were selected out according to the data from tag SNPs genotyped in the CHB (Han Chinese in Beijing, China) population sample of the international HapMap project (http://www.hapmap.org/index.html.zh).

DNA isolation kit from BioTeke (Peking, China) was used to extract genomic DNA from each individual’s blood sample according to the manufacturer’s instructions and the DNA products were stored at −20 °C for further genotype. The rs2228500 (A/G), rs4075913 (A/G), and rs11168417 (C/T) SNPs in the PFKM gene were genotyped using polymerase chain reaction–restriction
fragment length polymorphism (PCR–RFLP) analysis. Primers for PCR were designed by the online software Primer3.0. The primer sequences and the information about restriction enzymes for digesting PCR products are shown in Table 1. About 10% of the samples were randomly selected for repeated genotyping, thus the results were 100% consistent.

**Statistical analysis**

SPSS ver. 26.0 (SPSS Inc., Chicago, IL, USA) was applied to analyze all the data. The allele and genotype frequencies of the three selected SNPs were obtained through directed computing and the Hardy—Weinberg equilibrium was evaluated by chi-squared test. The genotype associations between the PFKM gene and cryptorchidism susceptibility were calculated by SNPstats online analysis software (https://www.snpstats.net/start.htm), which assessed the frequency distributions within four genetic models (codominant, dominant, recessive, and overdominant) in cryptorchidism patients and healthy controls. Odds ratio (OR) and respective 95% confidence interval (95%CI) were reported to evaluate the statistical differences between alleles and genotypes. *P* value <0.05 was considered as statistically significant.

**Results**

Three tag SNPs were genotyped in 140 cryptorchidism patients and 227 healthy control subjects. The genotype distributions of these polymorphisms all conformed to the Hardy–Weinberg equilibrium. The allele frequencies of the PFKM tag SNPs in patients with cryptorchidism and control individuals are summarized in Table 2. The allele frequencies of rs4075913 and rs11168417 polymorphisms have no significant differences between cryptorchidism patients and healthy controls. However, the frequency of the G allele of the rs2228500 in patients with cryptorchidism is significantly higher than those in controls (78% vs.69%). By contrast, the A allele frequencies of rs2228500 decreased (22% vs.31%) in the case group. A significantly increased cryptorchidism risk was found to be associated with the G allele of the rs2228500 (*p*=0.010, OR = 1.58, 95% CI 1.11–2.24).

As shown in Table 3, the genotype distributions of G/G, A/G, and A/A of rs2228500 were 60.7%, 33.6%, and 5.7% in the case group, and 46.3%, 44.9%, and 8.8% in the control group, respectively. Obviously, the significance could be observed in the codominant model (*p*=0.025). In the dominant model, compared with the G/G genotype, A/G–A/A genotypes were associated with a significantly decreased risk of cryptorchidism (*p*= 0.0069, OR = 1.80, 95% CI 1.17–2.75). No significant correlation was observed in any genetic models of rs4075913 and rs11168417 polymorphisms with the risk of cryptorchidism.

**Discussion**

Cryptorchidism refers to undescended testis, is one of the most frequent urogenital abnormalities in newborn boys [17], and it is the best-characterized risk factor for reduced fertility in males and testicular neoplasia [7]. In humans, testosterone and insulin-like factor 3 (INSL3) are the main regulators for testicular descending from the abdominal cavity to the bottom of the scrotum [18, 19]. Mutations in the genes

| Table 1 Information on primer and enzymes |
|------------------------------------------|
| **SNPs**       | **Primer (5’−3’)** | **Annealing temperature (°C)** | **Enzyme** | **Product length (bp)** |
|----------------|-------------------|-------------------------------|------------|------------------------|
| rs2228500      | F: tgtctctggggagctgactt  
R: acgcttcaccaggttgtagg | 58 | Hpy188I | 122 |
| rs11168417     | F: attactggcattttatgataacaac  
R: gccctcaacactacag | 60 | NdeI | 178 |
| rs4075913      | F: aagggggctttgtaaggt  
R: atggcattctatggttgg | 58 | DdeI | 90 |

SNP single-nucleotide polymorphism, *Bp* base pair
encode for INSL3 and its receptor and androgen receptors were considered to be the main cause of some forms of cryptorchidism [20–22]. Although some cases of cryptorchidism in humans can be attributed to known genetic defects and several pathogenetic mechanisms for cryptorchidism have been described, the exact cause of cryptorchidism in most patients remains unknown.

PFKM gene maps on chromosome 12q13.11 and its coding region consist of 2340 bp nucleotides, which encodes approximately 780 amino acids [23]. A key glycolytic regulatory enzyme, PFKM, which is concerned as an energy activator of muscle glycolysis, is encoded by the PFKM gene. Recently, there have been several researches focused on the association between PFKM mutations and different types of cancers, such as bladder cancer [24], breast cancer [25], and ovarian cancer [26], etc. Although some studies have confirmed the existence of specific PFKM in testis, there is no study on the correlation between PFKM gene and cryptorchidism. What is even more interesting is that earlier research in rat embryos indicated that growth retardation and congenital defects could be caused by interfering with glycolysis, which is an important source of ATP production [27]. As is known to us, PFKM is a pivotal regulator of cellular glycolysis by catalyzing the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate. PFKM deficiency is characterized by muscle weakness due to fuel crisis in exercising muscles [28]. Taken together, there may be a significant role of the PFKM gene plays in the

| Table 3. Distributions of PFKM SNPs among cryptorchidism patients and controls as well as their associations with cryptorchidism susceptibility |
|---------------------------------|-----------------|-----------------|-----------------|
| Genetic model                  | Genotype        | Patients         | Controls        | Logistic regression |
|                                | N=140 (%)       | N=227 (%)        | OR (95% CI)     | p                 |
| rs2228500                      |                  |                  |                 |                   |
| Codominant                     | G/G             | 85 (60.7)        | 105 (46.3)      | 1.00              |
|                                | A/G             | 47 (33.6)        | 102 (44.9)      | 1.76 (1.12–2.75)  |
|                                | A/A             | 8 (5.7)          | 20 (8.8)        | 2.02 (0.85–4.82)  |
| Dominant                       | G/G             | 85 (60.7)        | 105 (46.3)      | 1.00              |
|                                | A/G-A/A         | 55 (39.3)        | 122 (53.7)      | 1.80 (1.17–2.75)  |
| Recessive                      | G/G-G/G         | 132 (94.3)       | 207 (91.2)      | 1.00              |
|                                | A/A             | 8 (5.7)          | 20 (8.8)        | 1.59 (0.68–3.72)  |
| Overdominant                   | G/G-A/G/A       | 93 (66.4)        | 125 (55.1)      | 1.00              |
|                                | A/G             | 47 (33.6)        | 102 (44.9)      | 1.61 (1.04–2.50)  |
| Log-additive                   |                  |                  |                 |                   |
| rs4075913                      |                  |                  |                 |                   |
| Codominant                     | A/A             | 65 (47.1)        | 87 (39.5)       | 1.00              |
|                                | A/G             | 60 (43.5)        | 101 (45.9)      | 1.26 (0.80–1.98)  |
|                                | G/G             | 13 (9.4)         | 32 (14.6)       | 1.84 (0.89–3.78)  |
| Dominant                       | A/A             | 65 (47.1)        | 87 (39.5)       | 1.00              |
|                                | A/G–G/G         | 73 (52.9)        | 133 (60.5)      | 1.36 (0.89–2.09)  |
| Recessive                      | A/A–A/G/G       | 125 (90.6)       | 188 (85.5)      | 1.00              |
|                                | G/G             | 13 (9.4)         | 32 (14.6)       | 1.64 (0.83–3.24)  |
| Overdominant                   | A/A–G/A/G       | 78 (56.5)        | 119 (54.1)      | 1.00              |
|                                | A/G             | 60 (43.5)        | 101 (45.9)      | 1.10 (0.72–1.69)  |
| Log-additive                   |                  |                  |                 |                   |
| rs11168417                     |                  |                  |                 |                   |
| Codominant                     | C/C             | 111 (79.3)       | 194 (85.5)      | 1.00              |
|                                | C/T             | 28 (20)          | 30 (13.2)       | 0.61 (0.35–1.08)  |
|                                | T/T             | 1 (0.7)          | 3 (1.3)         | 1.72 (0.18–16.70) |
| Dominant                       | C/C             | 111 (79.3)       | 194 (85.5)      | 1.00              |
|                                | C/T–T/T         | 29 (20.7)        | 33 (14.5)       | 0.65 (0.38–1.13)  |
| Recessive                      | C/C–C/T         | 139 (99.3)       | 224 (98.7)      | 1.00              |
|                                | T/T             | 1 (0.7)          | 3 (1.3)         | 1.86 (0.19–18.07) |
| Overdominant                   | C/C–T/T         | 112 (80)         | 197 (86.8)      | 1.00              |
|                                | C/T             | 28 (20)          | 30 (13.2)       | 0.61 (0.35–1.07)  |
| Log-additive                   |                  |                  |                 |                   |

CI confidence interval, OR odds ratio. Bold values indicate a significant difference at the 5% level.
pathogenesis of cryptorchidism. Among the three tag SNPs we have chosen in PFKM, one SNP is located in the intron region and was observed to be associated with cryptorchidism risk, and the other two SNPs are located in the synonymous codon regions and both of them have no significant correlation with cryptorchidism risk. Julia et al. [29] identified that muscle patterning defect is associated with cryptorchidism in the rat fetal. Therefore, we suspected that the tag SNP rs2228500 may be affecting protein structure by influencing coding amino acids. In addition, it may affect the energy metabolism in the muscle of the glycolysis pathway, which may be a key factor in the lack of testicular descent motivation.

In summary, we investigated the impact of the PFKM gene polymorphism on cryptorchidism, and we observed significant differences in the frequency of alleles and genotypes at 1 tag SNP between patients and controls. We have offered primary evidence that the G allele and the G/G genotype of rs2228500 SNP in the PFKM gene are more frequent in patients with cryptorchidism than healthy controls. It implies that the polymorphism of the PFKM gene locus (rs2228500) may be a new genetic marker for cryptorchidism susceptibility and these alleles and genotypes may be risk factors for this disease.

Although we detected the association between the PFKM SNPs and cryptorchidism, there were certain limitations in this study. The sample size and ethnic types of this study were small and these results need to be further confirmed in a larger cohort. Moreover, the function and the underlying signal transduction mechanisms of the PFKM gene in cryptorchidism development need to be clarified.

Author contributions Data collection and curation: SL, BZ, RZ; Formal analysis: SL; Investigation: SL, YS, Qy; Methodology: SL, RZ; Supervision: BZ, YW, ZL; Validation: ZL; Manuscript writing: All authors approved final version of the manuscript.

Funding This work was supported by the National Natural Science Foundation of China (No. 81974226, No.32171264, No.81974365) and Department of Science and Technology of Sichuan Province (No.2021YS0026, No.2020ZYD007).

Declarations

Conflict of interest All authors declare that there is no conflict of interest regarding the publication of this paper.

References

1. Ghirri P, Ciulli C, Vuerich M, Cuttano A, Faraoni M, Guerrini L, et al (2002) Incidence at birth and natural history of cryptorchidism: a study of 10,730 consecutive male infants. J Endocrinol Invest 25(8):709–715. https://doi.org/10.1007/BF03345105 (Epub 2002/09/21 PubMed PMID: 12240903)
2. Dieckmann KP, Pichlmeyer U (2004) Clinical epidemiology of testicular germ cell tumors. World J Urol 22(1):2–14. https://doi.org/10.1007/s00345-004-0398-8 (Epub 2004/03/23 PubMed PMID: 15034740)
3. Lip SZ, Murchison LE, Cullis PS, Govan L, Carachi R (2013) A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. Arch Dis Child 98(1):20–26. https://doi.org/10.1136/archdischild-2012-302051 (Epub 2012/11/30 PubMed PMID: 23193201)
4. Kolon TF, Herndon CD, Baker LA, Baskin LS, Baxter CG, Cheng EY et al (2014) Evaluation and treatment of cryptorchidism: AUA guideline. J Urol 192(2):337–345. https://doi.org/10.1016/j.juro.2014.05.005 (Epub 2011/08/23, PubMed PMID: 24857650, PubMed PMID: 21855929)
5. Jensen MS, Olsen LH, Thulstrup AM, Bonde JP, Olsen J, Henriksen TB (2011) Age at cryptorchidism diagnosis and orchiopexy in Denmark: a population based study of 508,964 boys born from 1995 to 2009. J Urol 186(4 Suppl):1595–1600. https://doi.org/10.1016/j.juro.2011.03.070
6. Hutson JM (1985) A biphasic model for the hormonal control of testicular descent. Lancet 2(8452):419–421. https://doi.org/10.1016/s0140-6736(85)92739-4 (Epub 1985/08/24 PubMed PMID: 2863447)
7. Gurney JK, McGlynn KA, Stanley J, Merriman T, Signal V, Shaw C et al (2017) Risk factors for cryptorchidism. Nat Rev Urol 14(9):534–548. https://doi.org/10.1038/nrurrol.2017.90 (Epub 2017/06/28 PubMed PMID: 28654092; PubMed Central PMCID: PMCPMC5815831)
8. Al Hasawi N, Alkandari MF, Luqmani YA (2014) Phosphofructokinase in the rat testis: a mediator of glycolytic flux in cancer progression. Crit Rev Oncol Hematol 92(3):312–321. https://doi.org/10.1016/j.critrevonc.2014.05.007 (Epub 2014/06/10 PubMed PMID: 24910089)
9. Runaway GA, Kasten TP, Sebo T, Trapp R (1988) Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. Biochem J 251(3):677–683. https://doi.org/10.1042/bj2510677 (Epub 1988/05/01, PubMed PMID: 2970843; PubMed Central PMCID: PMCPMC1149058)
10. Webb BA, Forough F, Szu FE, Seetharaman J, Tong L, Barber DL (2015) Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations. Nature 523(7558):111–114. https://doi.org/10.1038/nature14405 (Epub 2015/05/20 PubMed PMID: 25985179)
11. Yi W, Clark PM, Mason DE, Keenan MC, Hill C, Goddard WA 3rd et al (2012) Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 337(6097):975–980. https://doi.org/10.1126/science.1222278 (Epub 2012/08/28, PubMed PMID: 22923583; PubMed Central PMCID: PMCPMC3534962)
12. Chen Y, Yu Q, Duan X, Wu W, Zeng G (2020) Phosphofructokinase-M inhibits cell growth via modulating the FOXO3 pathway in renal cell carcinoma cells. Biochem Biophys Res Commun 530(1):67–74. https://doi.org/10.1016/j.bbrc.2020.06.062 (Epub 2020/08/24, PubMed PMID: 32828317)
13. Lynn R, Gomes WR (1979) Phosphofructokinase in the rat testis during maturation and following heat treatment in vitro and in vivo. Biol Reprod 20(4):955–959. https://doi.org/10.1095/biolreprod20.4.955 (Epub 1979/05/01 PubMed PMID: 36934)
14. Lynn R, Gomes WR (1979) Phosphofructokinase in the rat testis: changes in isozyme patterns during maturation and short term cryptorchidism. Biol Reprod 20(4):961–964. https://doi.org/10.1095/biolreprod20.4.961 (Epub 1979/05/01 PubMed PMID: 36935)
15. Hutson JM, Hasthorpe S, Heyns CF (1997) Anatomical and functional aspects of testicular descent and cryptorchidism. Endocr Rev 18(2):259–280. https://doi.org/10.1210/edrv.18.2.0298 (Epub 1997/04/01, PubMed PMID: 9101140)

16. Scorer CG (1964) The descent of the testis. Arch Dis Child 39:605–609. https://doi.org/10.1136/adc.39.208.605 (Epub 1964/12/01 PubMed PMID: 14230757; PubMed Central PMCID: PMCPMC2019243)

17. Batra NV, DeMarco RT, Bayne CE (2021) A narrative review of the history and evidence-base for the timing of orchidopexy for cryptorchidism. J Pediatr Urol 17(2):239–245. https://doi.org/10.1016/j.jpuro.2021.01.013 (Epub 2021/02/09, PubMed PMID: 33551366)

18. Foresta C, Zuccarello D, Garolla A, Ferlin A (2008) Role of hormones, genes, and environment in human cryptorchidism. Endocr Rev 29(5):560–580. https://doi.org/10.1210/er.2007-0042 (Epub 2008/04/26, PubMed PMID: 18436703)

19. Hutson JM, Li R, Southwell BR, Newgreen D, Cousinery M (2015) Regulation of testicular descent. Pediatr Surg Int 31(4):317–325. https://doi.org/10.1007/s00383-015-3673-4 (Epub 2015/02/19 PubMed PMID: 25690562)

20. El Houate B, Rouba H, Sibai H, Barakat A, Chafik A, el Chadli B et al. (2007) Novel mutations involving the INSL3 gene associated with cryptorchidism. J Urol 177(5):1947–1951. https://doi.org/10.1016/j.juro.2007.01.002 (Epub 2007/04/18, PubMed PMID: 17437853)

21. Ferlin A, Rocca MS, Vinanzi C, Ghezzi M, Di Nisio A, Foresta C (2015) Mutational screening of NR5A1 gene encoding steroidogenic factor 1 in cryptorchidism and male factor infertility and functional analysis of seven undescribed mutations. Fertil Steril 104(1):163–9 e1. https://doi.org/10.1016/j.fertnstert.2015.04.017 (Epub 2015/05/21, PubMed PMID: 25989977)

22. Bay K, Main KM, Toppari J, Skakkebaek NE (2011) Testicular descent INSL3, testosterone, genes and the intrauterine milieu. Nat Rev Urol 8(4):187–196. https://doi.org/10.1038/nruro.2011.23 (Epub 2011/03/16, PubMed PMID: 21403659)

23. Fuji H, Miwa S (2000) Other erythrocyte enzyme deficiency associated with non-haematological symptoms: phosphoglycerate kinase and phosphofructokinase deficiency. Baillieres Best Pract Res Clin Haematol 13(1):141–148. https://doi.org/10.1053/beh.1999.0062 (Epub 2000/08/05, PubMed PMID: 10916683)

24. Sun CM, Xiong DB, Yan Y, Geng J, Liu M, Yao XD (2016) Genetic alteration in phosphofructokinase family promotes growth of muscle-invasive bladder cancer. Int J Biol Markers 31(3):e286–e293. https://doi.org/10.5310/ibm.500189 (Epub 2016/03/17, PubMed PMID: 26980488)

25. Ahsan H, Halpern J, Kibria MG, Pierce BL, Tong L, Gamazon E et al. (2014) A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. Cancer Epidemiol Biomarkers Prev 23(4):658–669. https://doi.org/10.1158/1055-9965.EPI-13-0340 (Epub 2014/02/05, PubMed PMID: 24493630; PubMed Central PMCID: PMCPMC3990360)

26. Gao W, Huang M, Chen X, Chen J, Zou Z, Li L et al. (2021) The role of S-nitrosylation of PFKM in regulation of glycolysis in ovarian cancer cells. Cell Death Dis 12(4):408. https://doi.org/10.1038/s41419-021-03681-0 (Epub 2021/04/17, PubMed PMID: 33859186; PubMed Central PMCID: PMCPMC8050300)

27. Villee CA (1984) Birth defects and glycolysis. N Engl J Med 310(4):254–255. https://doi.org/10.1056/NEJM198401263100408 (Epub 1984/01/26, PubMed PMID: 6690941)

28. Lee PA, Houk CP (2013) Cryptorchidism. Curr Opin Endocrinol Diabetes Obes 20(3):210–216. https://doi.org/10.1097/MED.0b013e32835fc7d (Epub 2013/03/16, PubMed PMID: 23493040)

29. Barthold JS, Robbins A, Wang Y, Pugarelli J, Mateson A, Anand-Ivell R et al. (2014) Cryptorchidism in the orl rat is associated with muscle patterning defects in the fetal gubernaculum and altered hormonal signaling. Biol Reprod 91(2):41 (Epub 2014/06/27, PubMed PMID: 24966393; PubMed Central PMCID: PMCPMC4435416)

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.